PL2311434T3 - Preparaty do inhalatora suchego proszku zawierające cząsteczki o zmodyfikowanej powierzchni z dodatkami zapobiegającymi adhezji - Google Patents

Preparaty do inhalatora suchego proszku zawierające cząsteczki o zmodyfikowanej powierzchni z dodatkami zapobiegającymi adhezji

Info

Publication number
PL2311434T3
PL2311434T3 PL10179073T PL10179073T PL2311434T3 PL 2311434 T3 PL2311434 T3 PL 2311434T3 PL 10179073 T PL10179073 T PL 10179073T PL 10179073 T PL10179073 T PL 10179073T PL 2311434 T3 PL2311434 T3 PL 2311434T3
Authority
PL
Poland
Prior art keywords
dry powder
powder inhaler
modified particles
particles
inhaler formulations
Prior art date
Application number
PL10179073T
Other languages
English (en)
Polish (pl)
Inventor
David Morton
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33548732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2311434(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of PL2311434T3 publication Critical patent/PL2311434T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Steroid Compounds (AREA)
PL10179073T 2004-11-23 2005-11-23 Preparaty do inhalatora suchego proszku zawierające cząsteczki o zmodyfikowanej powierzchni z dodatkami zapobiegającymi adhezji PL2311434T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0425758.0A GB0425758D0 (en) 2004-11-23 2004-11-23 Preparation of pharmaceutical compositions
EP05808842A EP1814521B1 (en) 2004-11-23 2005-11-23 Dry powder inhaler formulations comprising surface-modified particles with anti- adherent additives
EP10151576.5A EP2174653B1 (en) 2004-11-23 2005-11-23 Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives
EP10179073.1A EP2311434B1 (en) 2004-11-23 2005-11-23 Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives

Publications (1)

Publication Number Publication Date
PL2311434T3 true PL2311434T3 (pl) 2015-12-31

Family

ID=33548732

Family Applications (3)

Application Number Title Priority Date Filing Date
PL10179073T PL2311434T3 (pl) 2004-11-23 2005-11-23 Preparaty do inhalatora suchego proszku zawierające cząsteczki o zmodyfikowanej powierzchni z dodatkami zapobiegającymi adhezji
PL05808842T PL1814521T3 (pl) 2004-11-23 2005-11-23 Preparaty do inhalatora suchego proszku zawierające cząstki zmodyfikowane powierzchniowo ze środkami dodatkowymi przeciwdziałającymi adhezji
PL10151576T PL2174653T3 (pl) 2004-11-23 2005-11-23 Preparaty do inhalatora suchego proszku zawierające cząsteczki o zmodyfikowanej powierzchni z dodatkami zapobiegającymi adhezji

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL05808842T PL1814521T3 (pl) 2004-11-23 2005-11-23 Preparaty do inhalatora suchego proszku zawierające cząstki zmodyfikowane powierzchniowo ze środkami dodatkowymi przeciwdziałającymi adhezji
PL10151576T PL2174653T3 (pl) 2004-11-23 2005-11-23 Preparaty do inhalatora suchego proszku zawierające cząsteczki o zmodyfikowanej powierzchni z dodatkami zapobiegającymi adhezji

Country Status (16)

Country Link
US (4) US20080127972A1 (enExample)
EP (4) EP1814521B1 (enExample)
JP (2) JP5339401B2 (enExample)
CN (2) CN101106975A (enExample)
AT (1) ATE456363T1 (enExample)
CA (1) CA2589514C (enExample)
DE (1) DE602005019192D1 (enExample)
DK (2) DK2174653T3 (enExample)
ES (3) ES2490240T3 (enExample)
GB (1) GB0425758D0 (enExample)
HU (1) HUE027465T2 (enExample)
IN (1) IN2014CN04336A (enExample)
PL (3) PL2311434T3 (enExample)
PT (3) PT2311434E (enExample)
SI (2) SI2174653T1 (enExample)
WO (1) WO2006056812A1 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE382335T1 (de) 2000-11-30 2008-01-15 Vectura Ltd Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
KR100974482B1 (ko) 2003-03-27 2010-08-10 가부시키가이샤 바이오악티스 비강용 분말 약제 투약 장치
US20120321717A1 (en) * 2003-04-14 2012-12-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0621957D0 (en) * 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
DK2230934T3 (da) 2007-12-14 2012-11-26 Aerodesigns Inc Afgivelse af aerosoliserbare næringsmiddelprodukter
JP5936353B2 (ja) 2008-07-18 2016-06-22 プロソニックス リミテッドＰｒｏｓｏｎｉｘ Ｌｉｍｉｔｅｄ フルチカゾン粒子の結晶化度を改善する方法
AU2010229668C1 (en) 2009-03-26 2016-09-15 Pulmatrix Operating Co., Inc. Dry powder formulations and methods for treating pulmonary diseases
GB0905840D0 (en) * 2009-04-06 2009-05-20 Sagentia Ltd Apparatus and methods
MX2011011123A (es) * 2009-04-24 2011-11-04 Schering Corp Formulaciones de aglomerado utiles en inhaladores de polvo seco.
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
MX336414B (es) * 2010-04-01 2016-01-19 Chiesi Farma Spa Proceso de preparacion de particulas portadoras para polvos secos para inhalacion.
AU2011244384B2 (en) * 2010-04-21 2016-06-23 Chiesi Farmaceutici S.P.A. "Process for providing particles with reduced electrostatic charges"
CN102309456B (zh) * 2010-07-02 2013-05-01 北京化工大学 一种厄贝沙坦纳微复合粉体与片剂及其制备方法
EP2448571B1 (en) 2010-08-30 2013-06-12 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012050945A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
EP2621484A1 (en) * 2010-09-29 2013-08-07 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ITMI20120092A1 (it) * 2012-01-26 2013-07-27 Micro Macinazione S A Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia
EP2819672A1 (en) * 2012-02-29 2015-01-07 Pulmatrix, Inc. Inhalable dry powders
AU2013234080B2 (en) 2012-03-13 2016-12-22 Respivert Limited Novel pharmaceutical formulations
EP2836204B1 (en) 2012-04-13 2020-07-08 GlaxoSmithKline Intellectual Property Development Limited Aggregate particles
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
CN103588846B (zh) * 2012-08-15 2016-08-03 重庆华邦制药有限公司 一种丙酸氟替卡松微粒的制备方法及其用途
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
JP6116206B2 (ja) * 2012-11-26 2017-04-19 クリニプロ株式会社 吸入用パウダーの製造方法
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
US10149823B2 (en) * 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
US9402825B2 (en) 2013-07-11 2016-08-02 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
EP3738592B1 (en) 2013-10-08 2022-01-26 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
DK3107548T3 (da) * 2014-02-20 2022-07-18 Otitopic Inc Tørpulverformuleringer til inhalation
CA2944075C (en) 2014-04-04 2022-06-28 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
ES2701525T3 (es) 2014-07-09 2019-02-22 Arven Ilac Sanayi Ve Ticaret As Un procedimiento para la preparación de formulaciones para inhalación
CN107072947A (zh) 2014-07-31 2017-08-18 奥迪托皮克股份有限公司 用于吸入的干粉制剂
PT3191081T (pt) 2014-09-09 2020-05-29 Vectura Ltd Formulação que compreende glicopirrolato, método e equipamento
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US20160119692A1 (en) * 2014-10-24 2016-04-28 Sunshine Partners LLC Interactive system and method for viewer selection of objects in context while viewing television
EP3212212B1 (en) 2014-10-31 2020-09-23 Monash University Powder formulation
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US10853435B2 (en) 2016-06-17 2020-12-01 Axon Enterprise, Inc. Systems and methods for aligning event data
RU2767064C2 (ru) * 2016-06-30 2022-03-16 Филип Моррис Продактс С.А. Никотиносодержащие частицы и композиции
BR112018075017A2 (pt) 2016-06-30 2019-03-19 Philip Morris Products S.A. partículas de nicotina
WO2018071757A1 (en) * 2016-10-14 2018-04-19 Pulmatrix Operating Company, Inc. Antifungal dry powders
MX2019010263A (es) * 2017-03-07 2019-10-09 Philip Morris Products Sa Formulaciones de nicotina inhalables y metodos de fabricacion y uso de las mismas.
EP3630245A1 (en) 2017-06-02 2020-04-08 CSP Technologies, Inc. Inhaler and methods of using and making same
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN115919780A (zh) 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
JP2021509677A (ja) 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド 精密嗅覚装置によるオランザピンの鼻孔間送達
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
WO2023069028A1 (en) * 2021-10-20 2023-04-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
US12005185B2 (en) * 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods
WO2023128913A1 (en) * 2021-12-31 2023-07-06 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
WO2024009079A1 (en) 2022-07-04 2024-01-11 Hovione Scientia Limited Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation
CN115060832B (zh) * 2022-08-18 2022-11-29 上海奥科达生物医药科技有限公司 奥卡西平口服混悬液中奥卡西平及防腐剂含量检测方法
CN115770221A (zh) * 2022-12-29 2023-03-10 浙江上药九旭药业有限公司 银杏酮酯粉体、银杏酮酯滴丸剂及其制备方法
GB2641869A (en) 2023-08-30 2025-12-17 Envirohale Malta Holdings Ltd Nasal and pulmonary drug delivery
WO2025195446A1 (zh) * 2024-03-20 2025-09-25 浙江萃泽医药科技有限公司 一种可吸入的药物粉末制剂及其制备方法
CN119055610A (zh) * 2024-08-27 2024-12-03 江苏谦仁生物科技有限公司 一种阿昔莫司胶囊及其制备方法
CN119371006B (zh) * 2024-11-06 2025-07-04 北京城市排水集团有限责任公司 一种长效缓释型污泥脱氮菌群调节药剂及制备方法和应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687773A (en) 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
DE69034007T2 (de) 1989-04-28 2003-05-08 Riker Laboratories Inc., Northridge Inhalationsvorrichtung für Trockenpulver
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5292520A (en) 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
SA95160463B1 (ar) 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
FR2747311B1 (fr) 1996-04-10 1998-08-14 Pf Medicament Inhalateur a poudre et a air comprime
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
US6051257A (en) 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
EP0931595A1 (en) 1998-01-26 1999-07-28 Imra Europe S.A. A device for spraying a liquid
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DE59914603D1 (de) 1998-11-13 2008-02-14 Jagotec Ag Multidosis-Trockenpulverinhalator mit Pulverreservoir
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
DK1158958T3 (da) 1999-03-05 2007-10-08 Chiesi Farma Spa Forbedret pulverformulering til inhalering
KR100883477B1 (ko) 1999-05-27 2009-02-16 아쿠스피어 인코포레이티드. 다공성 약물 매트릭스의 약제 조성물
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
JP2001151673A (ja) 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
JP2001072586A (ja) 1999-09-06 2001-03-21 Nikken Chem Co Ltd 吸入用粉末製剤及びその製造方法
CN102584799A (zh) 1999-09-16 2012-07-18 田边三菱制药株式会社 含氮的6-员芳香环化合物
FI20002217A7 (fi) 1999-12-30 2001-07-01 Orion Yhtymae Oyj Inhalaatiopartikkelit
GB0008411D0 (en) * 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
US6506765B2 (en) 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
CA2406206C (en) 2000-04-17 2012-03-20 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0010709D0 (en) 2000-05-03 2000-06-28 Vectura Ltd Powders for use a in dry powder inhaler
US7744855B2 (en) 2000-06-27 2010-06-29 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB2364919A (en) 2000-07-21 2002-02-13 Cambridge Consultants Inhalers
WO2002009669A2 (en) 2000-08-01 2002-02-07 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution and particles made thereby
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20020086876A1 (en) 2000-11-15 2002-07-04 Ruff Dustin D. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
EP1341536A4 (en) 2000-11-15 2007-08-01 Tap Pharmaceutical Prod Inc TREATMENT OF SEXUAL DYSFUNCTION CAUSED BY ANTIDEPRESSIVE MEDICATION BY APOMORPHINE
AU2002220857A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Particles for use in a pharmaceutical composition
NZ526059A (en) * 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
WO2002043693A2 (en) 2000-11-30 2002-06-06 Vectura Limited Pharmaceutical compositions for inhalation
ATE382335T1 (de) * 2000-11-30 2008-01-15 Vectura Ltd Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation
DK1353647T3 (da) 2000-12-27 2011-06-14 Gilead Sciences Inc Inhalerbar aztreonam til behandling og forebyggelse af bakterielle lungeinfektioner
GB0109384D0 (en) * 2001-04-12 2001-05-30 Vectura Ltd Pharmaceutical products, preparation and uses thereof
JP2005506855A (ja) 2001-05-10 2005-03-10 ベクトゥラ デリバリー デバイシーズ リミテッド 吸入器
GB2375308A (en) 2001-05-10 2002-11-13 Cambridge Consultants Inhalers
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
WO2003020241A2 (en) * 2001-09-05 2003-03-13 Vectura Limited Functional powders for oral delivery
EP1490031A1 (en) * 2002-03-07 2004-12-29 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US20040003341A1 (en) 2002-06-20 2004-01-01 Koninklijke Philips Electronics N.V. Method and apparatus for processing electronic forms for use with resource constrained devices
CA2500923A1 (en) * 2002-10-11 2004-04-22 Vectura Limited Pharmaceutical excipients comprising inorganic particles in association with an organic polymeric material and forming a solid reticulated matrix, compositions, manufacturing and use thereof
US20040204439A1 (en) 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
AU2004228757A1 (en) 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
WO2004093848A2 (en) 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
WO2005025535A2 (en) * 2003-09-15 2005-03-24 Vectura Limited Methods for preparing pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0330255D0 (en) 2003-12-31 2004-02-04 Vectura Ltd Multiparticulate formulations for oral delivery
GB0408308D0 (en) 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
CN104146960A (zh) 2014-11-19
JP5339401B2 (ja) 2013-11-13
EP1814521B1 (en) 2010-01-27
SI2174653T1 (sl) 2014-10-30
ES2548884T3 (es) 2015-10-21
US20170216203A1 (en) 2017-08-03
DK2311434T3 (en) 2015-10-05
ES2490240T3 (es) 2014-09-03
US9642800B2 (en) 2017-05-09
EP2949317A1 (en) 2015-12-02
DK2174653T3 (da) 2014-08-11
CN101106975A (zh) 2008-01-16
EP2311434A1 (en) 2011-04-20
EP1814521A1 (en) 2007-08-08
US20160000709A1 (en) 2016-01-07
US20110236492A1 (en) 2011-09-29
WO2006056812A1 (en) 2006-06-01
ES2340599T3 (es) 2010-06-07
EP2174653A1 (en) 2010-04-14
PL2174653T3 (pl) 2014-11-28
JP2011201925A (ja) 2011-10-13
GB0425758D0 (en) 2004-12-22
US9585834B2 (en) 2017-03-07
PT1814521E (pt) 2010-04-16
IN2014CN04336A (enExample) 2015-09-04
JP2008520307A (ja) 2008-06-19
EP2949317B1 (en) 2017-01-04
PL1814521T3 (pl) 2010-07-30
PT2311434E (pt) 2015-10-23
CA2589514C (en) 2014-07-22
PT2174653E (pt) 2014-08-25
CA2589514A1 (en) 2006-06-01
DE602005019192D1 (de) 2010-03-18
JP5579669B2 (ja) 2014-08-27
EP2174653B1 (en) 2014-05-14
SI2311434T1 (sl) 2015-11-30
HUE027465T2 (en) 2016-09-28
US20080127972A1 (en) 2008-06-05
ATE456363T1 (de) 2010-02-15
EP2311434B1 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
PT2174653E (pt) Formulações para inalador de pó seco compreendendo partículas modificadas na superfície com aditivos antiaderentes
SG161203A1 (en) Nanoparticulate tacrolimus formulations
WO2008084312A3 (en) Micronised particles of low-dosage strength active agents for powder formulations for inhalation
EP1915163A4 (en) COMPOSITIONS OF POLYETHYL AND POLYETHERS AND METHOD FOR THEIR USE AS SKIN FILLERS
MX2009005727A (es) Nanoparticulas de entidad anfifilica.
WO2007053197A3 (en) Nanoparticulate acetaminophen formulations
AU2003234452A1 (en) Nanoparticulate nystatin formulations
NZ573555A (en) Nanoparticulate posaconazole formulations
TW200613479A (en) Coating formulation having improved rheological properties
IL218317A (en) Use of 15-il polypeptide preparations and 15-il complexes for the preparation of cancer drugs
WO2008008733A3 (en) Nanoparticulate sorafenib formulations
MY155299A (en) Oral dosage composition
MY150531A (en) Anti-cd79b antibodies and immunoconjugates and methods of use
MXPA02012023A (es) Administracion altamente eficiente de un aerosol de masa terapeutica grande.
BR0110139A (pt) Formulações farmacêuticas para inaladores de pó seco
EP2571486A4 (en) DRY POWDER INHALATION COMPOSITION
MX2011012196A (es) Composiciones y metodos para el suministro de farmaco.
PT1337239E (pt) Partículas servindo à preparação de uma composição farmacêutica
MX368774B (es) Nueva dosificación y formulación.
DE60234945D1 (de) Pulver zur nasalen verabreichung von wirkstoffen
WO2006008517A3 (en) Use of dry powder compositions for pulmonary delivery
MX2009008487A (es) Picoplatino encapsulado.
WO2005041922A3 (en) Composition
WO2008066810A3 (en) Pleasant tasting dry powder compositions suitable for pulmonary delivery
PL2051693T3 (pl) Kompozycja farmaceutyczna, łatwa do połknięcia i nie powodująca nieprzyjemnych odczuć w ustach, zawierająca cząstki z substancją czynną